OncoMatch/Clinical Trials/NCT04080804
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
Is NCT04080804 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Relatlimab for head and neck squamous cell carcinoma (hnscc).
Treatment: Nivolumab · Relatlimab · Ipilimumab — The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: LAG3 any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Prior radiation ... [excluded]
Cannot have received: chemotherapy
Prior ... chemotherapy ... [excluded]
Cannot have received: oncology vaccine
Prior ... oncology vaccine ... [excluded]
Cannot have received: immunotherapy
Prior ... immunotherapy [excluded]
Cannot have received: LAG-3 targeted agent
Prior treatment with LAG-3 targeted agents
Lab requirements
Cardiac function
LVEF ≥50% by TTE or MUGA within 28 days prior to first study drug administration; Troponin T or I ≤ 2 × institutional ULN (with retesting/monitoring as described)
LVEF assessment with documented LVEF ≥50% by either TTE or MUGA ... Troponin T (TnT) or I (TnI) > 2 × institutional ULN [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify